SAN DIEGO, May 13, 2016 /PRNewswire/ -- ResMed
(NYSE:RMD) the world's leading tech-driven medical device company
and innovator in sleep-disordered breathing and respiratory care,
announced today that the United States International Trade
Commission (ITC) has accepted its request to investigate alleged
infringement of its patented technology by Chinese medical device
manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B
Medical.
The ITC has agreed to review the alleged infringement of four
ResMed patents by BMC's first and second generation flow generator
products, the RESmart and the Luna. The ResMed patents cover
ResMed's innovative flow generators and ventilators, including:
- U.S. Patent No. RE44,453, relating to a flow generator and
humidifier structured to reduce the risk of backflow of water from
the humidifier into the flow generator when tipped, and
- U.S. Patent Nos. 8,006,691, 8,020,551 and 9,072,860, each
relating to a novel design for a flow generator and humidifier to
improve performance and ease of use.
The U.S. ITC Notice of Institution of Investigation can be found
here: http://1.usa.gov/1VV2GxO
Based on a previous challenge from BMC, the United States Patent
and Trademark Office rendered a final decision in January 2016 upholding the validity of the
asserted claims from ResMed's 453 patent; BMC did not appeal that
ruling.
ResMed is asking the ITC to stop BMC and 3B from importing and
selling flow generators in the United
States based on the alleged infringement of its patents.
ResMed has also filed a lawsuit in federal court in San Diego seeking damages.
"ResMed has developed leading edge solutions for the treatment
of sleep apnea and other respiratory conditions," said ResMed's
global general counsel and chief administrative officer
David Pendarvis. "ResMed's
proprietary innovations provide key benefits to patients, including
increased comfort and usability, that help with successful CPAP
therapy. We are appreciative of the ITC's decision to investigate
the alleged infringement. We will continue to defend our
proprietary technology that underscores the high-quality solutions
we provide to patients in the United
States and around the world."
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 1 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries. Find more about ResMed at
ResMed.com, Facebook, Twitter and LinkedIn.
Contacts:
|
|
For News
Media:
|
For
Investors:
|
Alison Graves
|
Agnes Lee
|
Public Relations
Manager
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/international-trade-commission-to-investigate-chinese-manufacturer-bmc-medicals-infringement-of-resmed-patents-300268180.html
SOURCE ResMed Inc.